Our Science
OUR SCIENCE
Congress Presentations
This section includes posters and presentations related to Arvinas’ PROTAC science, discovery compounds, and clinical-stage assets presented at scientific congresses in the past three years.*
ICML 2025 | Lugano, Switzerland
Jun 17 - 21, 2025
Poster
ARV-393, a PROteolysis TArgeting Chimera (PROTAC) BCL6 Degrader, Combined With Biologics or Small-Molecule Inhibitors Induces Tumor Regressions in Diffuse Large B-Cell Lymphoma ModelsEHA 2025 | Milan, Italy
Jun 12 - 15, 2025
Poster
ARV-393, a PROteolysis TArgeting Chimera (PROTAC) BCL6 Degrader, is Efficacious in Preclinical Models of Diffuse Large B-Cell Lymphoma, Nodal T-Follicular Helper Cell Lymphoma, and Transformed Follicular LymphomaASCO 2025 | Chicago, IL
May 30 - Jun 3, 2025
Presentation
Vepdegestrant, a PROTAC Estrogen Receptor (ER) Degrader, vs Fulvestrant in ER-Positive/Human Epidermal Growth Factor Receptor 2 (HER2)–Negative Advanced Breast Cancer: Results of the Global, Randomized, Phase 3 VERITAC-2 StudyASCPT 2025 | Washington, DC
May 28 - 31, 2025
Poster
The Effect of Carbamazepine on the Pharmacokinetics of Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor Degrader, in Healthy AdultsIAPRD 2025 | New York City, NY
May 7 - 10, 2025
Poster
First-in-Human Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of ARV-102, a PROTAC LRRK2 Degrader, in Healthy VolunteersAACR 2025 | Chicago, IL
Apr 25 - 30, 2025
Poster
ARV-393, a PROteolysis TArgeting Chimera (PROTAC) BCL6 Degrader, Combined With Biologics or Small-Molecule Inhibitors Induces Tumor Regressions in Diffuse Large B-Cell Lymphoma ModelsAD/PD 2025 | Vienna, Austria
Apr 1 - 5, 2025
Presentation
First-In-Human Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of ARV-102, a PROTAC LRRK2 Degrader, in Healthy VolunteersSABCS 2024 | San Antonio, TX
Dec 10 - 13, 2024
Poster
Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor Degrader, Plus Abemaciclib in Estrogen Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced or Metastatic Breast Cancer: TACTIVE-U Preliminary Phase 1b ResultsSABCS 2024 | San Antonio, TX
Dec 10 - 13, 2024
Poster
Evaluating CYP3A4-Mediated Drug Interaction Risks for Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor Degrader, in Combination With Cyclin-Dependent Kinase 4/6 Inhibitors and Everolimus* Vepdegestrant (VEPPANU™) is licensed to Rigel Pharmaceuticals, which holds the exclusive global development, manufacturing, and commercialization rights.